Identifying patients for CAMZYOS (mavacamten)

CAMZYOS is the only licensed non-invasive oral therapy that targets the underlying pathophysiology of obstructive HCM¹, and therefore ensuring suitable patients are initiated on CAMZYOS as early as possible is paramount.

What factors do you need to consider to determine if your patient has obstructive HCM and may be suitable for CAMZYOS?

The CAMZYOS checklist

Adult (≥18 years old)¹

Family history of one or more of the following:^2,3

Cardiomyopathy
Sudden cardiac death
Arrhythmias or unexplained syncope
Other inherited cardiac conditions

Confirmed or suspected obstructive HCM¹

Peak LVOT obstruction gradient ≥50 mmHg at rest or with provocation⁴

One or more of the following potential signs and symptoms suggestive of NYHA class II–III HCM:⁵

Peak LVOT obstruction gradient ≥50 mmHg at rest or with provocation
Fatigue or tiredness
Shortness of breath (also during activity)
Chest pain (angina)
Syncope
Dizziness or light headedness
Palpitations
Arrhythmias
Orthopnoea
Pulmonary congestion
Excessive sweating

Download the CAMZYOS checklist and keep to hand to help you identify patients who may be suitable for CAMZYOS

Download CAMZYOS checklist

You've identified that your patient may be suitable for CAMZYOS, what's next?

If you think your patient is suitable for CAMZYOS, the next step is to promptly refer them to an Inherited Cardiac Conditions (ICC) centre.

Why is prompt referral important?

The signs and symptoms of obstructive HCM can have a great impact on patient's lives, for example:^5,6

A limited capacity to be physically active
Limitation on daily tasks
Emotional toll
Anxiety and/or depression
Affected ability to work
Disrupted family and social life
Poor sleep quality

Furthermore, the potential complications associated with obstructive HCM include:^5,7–9

Heart failure
Cardiac arrest
Endocarditis
Stroke
Atrial fibrillation

An ICC centre will confirm diagnosis, assess suitability for CAMZYOS, and develop a management plan.³ Find an ICC Centre

Explore hypothetical patients who may be suitable for CAMZYOS –
do you see patients like these in your practice?

Patient profiles

HCM, hypertrophic cardiomyopathy; ICC, Inherited Cardiac Conditions; LVOT, left ventricular outflow obstruction; NYHA, New York Heart Association.

References

CAMZYOS (mavacamten) Summary of Product Characteristics.
Alway T et al. Br Med Bull. 2024;150(1):11–22.
Association for Inherited Cardiac Conditions. ICC Referral Pathway. Available at: https://www.theaicc.org/clinical-icc-pathways Date accessed: September 2025.
Arbelo E et al. Eur Heart J. 2023;44(37):3503–3626.
Zaiser E et al. J Patient Rep Outcomes. 2020;4(1):102.
Konecny T, Somers VK. Chest. 2014;146(1):228–234.
Maron BJ et al. J Am Coll Cardiol. 2002;39(2):301–307.
O’Mahony C et al. Circ Arrhythm Electrophysiol. 2013;6(2):443–451.
Ho CY et al. Circulation. 2018;138(14):1387–1398.

3500-GB-2500117 | September 2025